-
2023-503708-10-00
5
2024-02-20
Locally advanced or metastatic breast cancer
-
2022-500531-36-00
4
2024-02-02
Type 1 diabetes mellitus
-
2022-502113-28-00
5
2024-02-01
Follicular lymphoma
-
2024-518888-35-00
4
2024-01-24
amyotrophic lateral sclerosis patients
-
2022-503092-28-00
5
2024-01-08
Relapsed/Refractory Follicular Lymphoma
-
2022-502775-29-01
5
2023-12-14
Early stage Follicular Lymphoma
-
2022-502950-14-00
6
2023-12-08
Partial Lipodystrophy
-
2023-509793-38-00
4
2023-11-24
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or CLL-like mo
-
2022-502273-42-00
5
2023-11-08
Glaucoma
-
2022-502597-16-00
9
2023-10-27
Intermediate or High-risk Primary or Secondary
Myelofibrosis
-
2023-504602-11-00
5
2023-10-25
Mild to moderate Alzheimer's disease
-
2023-510431-11-00
4
2023-07-21
Chronic Lymphocytic Leukemia
-
2022-500587-35-01
5
2023-07-06
Stroke
-
2022-501808-96-00
4
2023-05-15
Mantle Cell Lymphoma
-
2024-520119-41-00
4
2023-01-15
Previously untreated patients with diagnosis of HCL
-
2022-502140-13-00
6
2023-01-11
Atrial fibrillation
Acute coronary syndrome
Chronic coronary syndrome
-
2023-510240-20-00
4
2022-10-05
Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
-
2023-510384-36-00
5
2022-09-13
Newly Diagnosed Multiple Myeloma
-
2023-510346-25-00
5
2022-09-01
Hypereosinophilic Syndrome (HES)
-
2024-514687-33-00
4
2021-12-21
Previously Untreated Chronic Lymphophatic Leukaemia
-
2024-515361-34-00
6
2021-10-13
Patients with atrial fibrillation undergoing percutaneous left atrial
-
2024-519007-10-00
10
2020-10-22
Locally advanced stage II/III rectal cancer
-
2023-510433-29-00
5
2020-09-24
Favorable-intermediate-risk Acute Myeloid Leukemia
-
2023-505901-17-00
5
2020-04-24
Acute Myeloid Leukemia (LMA) with FLT3 mutation